FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567603273> ?p ?o ?g. }

• W1567603273 endingPage "385" @default.
• W1567603273 startingPage "373" @default.
• W1567603273 abstract "Objective To assess the efficacy of fesoterodine 8 mg vs extended‐release ( ER ) tolterodine 4 mg for overactive bladder ( OAB ) symptoms in terms of patient‐reported outcomes in women and in men. Subjects and Methods Pooled data from two 12‐week, randomized, double‐blind, double‐dummy studies were analysed. Participants eligible for the studies were ≥18 years old, had self‐reported OAB symptoms for ≥3 months in 3‐day baseline diaries and had ≥8 micturitions and ≥1 urgency urinary incontinence ( UUI ) episode per 24 h. Individuals were randomized to fesoterodine (4 mg for 1 week then 8 mg for 11 weeks), ER tolterodine (4 mg), or placebo. Changes from baseline in 3‐day bladder diary variables and scores from the P atient P erception of B ladder C ondition ( PPBC ), U rgency P erception S cale ( UPS ), and O veractive B ladder Q uestionnaire ( OAB ‐q), were assessed, as was the ‘diary‐dry’ rate (the proportion of subjects with >0 UUI episodes according to baseline diary and no UUI episodes according to post‐baseline diary). The primary endpoint was the change from baseline to week 12 in UUI episodes. Results At week 12, women showed significantly greater improvement with fesoterodine 8 mg ( n = 1374) than with ER tolterodine 4 mg ( n = 1382) and placebo ( n = 679) in UUI episodes (primary endpoint), micturition frequency, urgency episodes, and all other diary endpoints (except nocturnal micturitions versus ER tolterodine), and also in scores on the PPBC , UPS , and all OAB ‐q scales and domains (all P < 0.005). Diary‐dry rates in women were significantly greater with fesoterodine (63%) than with tolterodine (57%; P = 0.002) or placebo (48%; P < 0.0001). In men, there were no significant differences in improvement in UUI episodes between any treatment groups at week 12. Improvements in men were significantly greater with fesoterodine 8 mg ( n = 265) than with ER tolterodine ( n = 275) for severe urgency and the OAB ‐q Symptom Bother domain and were also significantly greater with fesoterodine than with placebo ( n = 133) for micturition frequency, urgency episodes, severe urgency episodes, PPBC responses and scores on all OAB ‐q scales and domains at week 12 (all P < 0.04). The most frequently reported treatment‐emergent adverse events in both genders were dry mouth (women: fesoterodine, 29%; ER tolterodine, 15%; placebo, 6%; men: fesoterodine, 21%; ER tolterodine, 13%; placebo, 5%) and constipation (women: fesoterodine, 5%; ER tolterodine, 4%; placebo, 2%; men: fesoterodine, 5%; ER tolterodine, 3%; placebo, 1%). Urinary retention rates were low in women (fesoterodine, <1%; ER tolterodine, <1%; placebo, 0%) and men (fesoterodine, 2%; ER tolterodine <1%; placebo, 2%). Conclusion This analysis supports the superiority of fesoterodine 8 mg over ER tolterodine 4 mg on diary endpoints, including UUI , symptom bother and health‐related quality of life in women. In men, fesoterodine 8 mg was superior to ER tolterodine 4 mg for improving severe urgency and symptom bother." @default.
• W1567603273 created "2016-06-24" @default.
• W1567603273 creator A5002038596 @default.
• W1567603273 creator A5013290978 @default.
• W1567603273 creator A5027796118 @default.
• W1567603273 creator A5060991124 @default.
• W1567603273 creator A5074097027 @default.
• W1567603273 creator A5080431551 @default.
• W1567603273 creator A5090695716 @default.
• W1567603273 date "2013-07-04" @default.
• W1567603273 modified "2023-10-17" @default.
• W1567603273 title "Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder" @default.
• W1567603273 cites W1531562711 @default.
• W1567603273 cites W1579998465 @default.
• W1567603273 cites W1590256680 @default.
• W1567603273 cites W1597047387 @default.
• W1567603273 cites W1834240270 @default.
• W1567603273 cites W1967347194 @default.
• W1567603273 cites W1968865622 @default.
• W1567603273 cites W1975761784 @default.
• W1567603273 cites W1981455401 @default.
• W1567603273 cites W1982223434 @default.
• W1567603273 cites W1983307152 @default.
• W1567603273 cites W1986753920 @default.
• W1567603273 cites W1987111921 @default.
• W1567603273 cites W1998053348 @default.
• W1567603273 cites W2008825099 @default.
• W1567603273 cites W2014737244 @default.
• W1567603273 cites W2025864351 @default.
• W1567603273 cites W2026599479 @default.
• W1567603273 cites W2028950772 @default.
• W1567603273 cites W2034265241 @default.
• W1567603273 cites W2041666025 @default.
• W1567603273 cites W2054263301 @default.
• W1567603273 cites W2064365016 @default.
• W1567603273 cites W2065160248 @default.
• W1567603273 cites W2067889220 @default.
• W1567603273 cites W2068613976 @default.
• W1567603273 cites W2077126096 @default.
• W1567603273 cites W2089028166 @default.
• W1567603273 cites W2114346603 @default.
• W1567603273 cites W2119098706 @default.
• W1567603273 cites W2131770336 @default.
• W1567603273 cites W2134928141 @default.
• W1567603273 cites W2169965447 @default.
• W1567603273 cites W2323322406 @default.
• W1567603273 doi "https://doi.org/10.1111/bju.12174" @default.
• W1567603273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23826844" @default.
• W1567603273 hasPublicationYear "2013" @default.
• W1567603273 type Work @default.
• W1567603273 sameAs 1567603273 @default.
• W1567603273 citedByCount "34" @default.
• W1567603273 countsByYear W15676032732013 @default.
• W1567603273 countsByYear W15676032732014 @default.
• W1567603273 countsByYear W15676032732015 @default.
• W1567603273 countsByYear W15676032732016 @default.
• W1567603273 countsByYear W15676032732017 @default.
• W1567603273 countsByYear W15676032732018 @default.
• W1567603273 countsByYear W15676032732019 @default.
• W1567603273 countsByYear W15676032732021 @default.
• W1567603273 countsByYear W15676032732022 @default.
• W1567603273 countsByYear W15676032732023 @default.
• W1567603273 crossrefType "journal-article" @default.
• W1567603273 hasAuthorship W1567603273A5002038596 @default.
• W1567603273 hasAuthorship W1567603273A5013290978 @default.
• W1567603273 hasAuthorship W1567603273A5027796118 @default.
• W1567603273 hasAuthorship W1567603273A5060991124 @default.
• W1567603273 hasAuthorship W1567603273A5074097027 @default.
• W1567603273 hasAuthorship W1567603273A5080431551 @default.
• W1567603273 hasAuthorship W1567603273A5090695716 @default.
• W1567603273 hasBestOaLocation W15676032731 @default.
• W1567603273 hasConcept C126322002 @default.
• W1567603273 hasConcept C126894567 @default.
• W1567603273 hasConcept C142724271 @default.
• W1567603273 hasConcept C168563851 @default.
• W1567603273 hasConcept C175768497 @default.
• W1567603273 hasConcept C203092338 @default.
• W1567603273 hasConcept C204787440 @default.
• W1567603273 hasConcept C27081682 @default.
• W1567603273 hasConcept C2778531004 @default.
• W1567603273 hasConcept C2778941218 @default.
• W1567603273 hasConcept C2781020410 @default.
• W1567603273 hasConcept C3020385749 @default.
• W1567603273 hasConcept C71924100 @default.
• W1567603273 hasConcept C77411442 @default.
• W1567603273 hasConcept C98274493 @default.
• W1567603273 hasConceptScore W1567603273C126322002 @default.
• W1567603273 hasConceptScore W1567603273C126894567 @default.
• W1567603273 hasConceptScore W1567603273C142724271 @default.
• W1567603273 hasConceptScore W1567603273C168563851 @default.
• W1567603273 hasConceptScore W1567603273C175768497 @default.
• W1567603273 hasConceptScore W1567603273C203092338 @default.
• W1567603273 hasConceptScore W1567603273C204787440 @default.
• W1567603273 hasConceptScore W1567603273C27081682 @default.
• W1567603273 hasConceptScore W1567603273C2778531004 @default.
• W1567603273 hasConceptScore W1567603273C2778941218 @default.
• W1567603273 hasConceptScore W1567603273C2781020410 @default.
• W1567603273 hasConceptScore W1567603273C3020385749 @default.

• next